Development and Validation of a Good Manufacturing Process for IL-4-Driven Expansion of Chimeric Cytokine Receptor-Expressing CAR T-Cells

Adoptive cancer immunotherapy using chimeric antigen receptor (CAR) engineered T-cells holds great promise, although several obstacles hinder the efficient generation of cell products under good manufacturing practice (GMP). Patients are often immune compromised, rendering it challenging to produce...

Descripción completa

Detalles Bibliográficos
Autores principales: van Schalkwyk, May C. I., van der Stegen, Sjoukje J. C., Bosshard-Carter, Leticia, Graves, Helen, Papa, Sophie, Parente-Pereira, Ana C., Farzaneh, Farzin, Fisher, Christopher D., Hope, Andrew, Adami, Antonella, Maher, John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8307141/
https://www.ncbi.nlm.nih.gov/pubmed/34359966
http://dx.doi.org/10.3390/cells10071797

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8307141/
https://www.ncbi.nlm.nih.gov/pubmed/34359966
http://dx.doi.org/10.3390/cells10071797

Ejemplares similares